Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: May 30, 2023

CLINICAL TRIALS PROFILE FOR ALKERAN

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Alkeran

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002556 ↗	Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 3	1994-07-01	This randomized phase III clinical trial studies combination chemotherapy with high dose cyclophosphamide and recombinant interferon alfa-2b to see how well it works compared to combination chemotherapy alone in treating patients with previously untreated stage I-III multiple myeloma. Drugs used in chemotherapy, such as vincristine sulfate, carmustine, melphalan, cyclophosphamide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of cancer cells. It is not yet know whether giving combination chemotherapy with or without alternating high-dose cyclophosphamide and recombinant interferon alfa-2b is more effective in treating multiple myeloma.
NCT00002594 ↗	Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors	Completed	National Cancer Institute (NCI)	Phase 2	1994-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so that they stop growing or die. bone marrow transplantation and peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow transplantation and/or peripheral stem cell transplantation in treating patients who have recurrent medulloblastoma or CNS germ cell tumors.
NCT00002594 ↗	Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors	Completed	Children's Oncology Group	Phase 2	1994-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so that they stop growing or die. bone marrow transplantation and peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow transplantation and/or peripheral stem cell transplantation in treating patients who have recurrent medulloblastoma or CNS germ cell tumors.
NCT00002835 ↗	Combination Chemotherapy in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1995-10-30	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
NCT00002835 ↗	Combination Chemotherapy in Treating Patients With Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 3	1995-10-30	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Alkeran

Condition Name

Chart
Table

Condition Name for Alkeran
Intervention	Trials
Multiple Myeloma	38
Lymphoma	27
Leukemia	24
Myeloma	15
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Alkeran
Intervention	Trials
Multiple Myeloma	73
Neoplasms, Plasma Cell	63
Lymphoma	48
Leukemia	40
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Alkeran

Trials by Country

Map
Table

Trials by Country for Alkeran
Location	Trials
United States	512
Canada	25
Australia	9
Italy	7
Switzerland	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Alkeran
Location	Trials
Texas	54
California	31
New York	30
Massachusetts	22
Illinois	20
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Alkeran

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Alkeran
Clinical Trial Phase	Trials
Phase 3	15
Phase 2/Phase 3	5
Phase 2	85
[disabled in preview]	60
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Alkeran
Clinical Trial Phase	Trials
Completed	84
Recruiting	31
Active, not recruiting	26
[disabled in preview]	34
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Alkeran

Sponsor Name

Chart
Table

Sponsor Name for Alkeran
Sponsor	Trials
National Cancer Institute (NCI)	64
M.D. Anderson Cancer Center	44
Masonic Cancer Center, University of Minnesota	12
[disabled in preview]	19
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Alkeran
Sponsor	Trials
Other	211
NIH	70
Industry	43
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow

AstraZeneca

Express Scripts

Colorcon

Merck

Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.